

**Client**  
**Gurugram**  
Pathkind Diagnostics Pvt. Ltd.  
Plot No. 55-56, Udhog Vihar Ph-IV, Gurugram - 122015

**Processed By**  
**Pathkind Diagnostics Pvt. Ltd.**  
Plot No. 55-56, Udhog Vihar Ph-IV, Gurugram - 122015

<b>Name</b> : Mr. FC35	<b>Billing Date</b> : 07/07/2023 12:23:59
<b>Age</b> : 35 Yrs	<b>Sample Collected on</b> : 10/07/2023 10:01:31
<b>Sex</b> : Male	<b>Sample Received on</b> : 10/07/2023 11:02:13
<b>P. ID No.</b> : P1000100012775	<b>Report Released on</b> : 20/07/2023 15:52:35
<b>Accession No</b> : 10002304831	<b>Barcode No.</b> : 10002304831-01
<b>Referring Doctor</b> : Self	<b>Ref no.</b> :
<b>Referred By</b> :	

**Report Status - Final**

Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

**HAEMATOLOGY**

**# Flowcytometry MM MRD**

Sample: B.Marrow Heparinized

**Immunophenotyping findings** – The flowcytometric immunophenotyping of bone marrow aspirate sent for minimal residual disease (MRD) analysis in a known case of Plasma Cell Myeloma does not show any abnormal Plasma Cell population.

**Impression:** Minimal Residual Disease (MRD): Negative (in a k/c/o Plasma Cell Myeloma)

**Advice:** Clinical and morphologic correlation is recommended.

**Markers used:** CD45, CD19, CD20, CD38, CD138, CD56, CD117, KAPPA, LAMBDA.

**Comment:** The samples was run on BC Navios 10 color flow-cytometer as per the standardized international protocol. FSC vs SSC was used to gate viable cells. CD45vs SSC gating strategy is used.

Software used for analysis is Kaluza 2.1.3

Note: Investigation should be interpreted understanding the limitation of the sample quality and various statistical parameters. An isolated laboratory report never forms a basis of any treatment decision. It should always be interpreted with the clinical course by the primary

\*\* End of Report\*\*



**Dr. Aarti Khanna Nagpal**

DNB (Pathology)  
Senior Consultant

10002304831 Mr. FC35

Page No: 1 of 1

